A letter to the editor raising concerns about the generalizability and outcome measures of the SPRINT trial in older adults.
To the Editor The SPRINT Research Group1 provided evidence to guide antihypertensive management practice in persons aged 75 years or older. However, we are concerned about the generalizability of the study and the nature of the outcome measures used.
No takes yet. Share an insight, caveat, or question.
Dimitri et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: